deltatrials
Unknown PHASE2 NCT00006115

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Alternation of FOLFOX6 (Oxaliplatin - Leucovorin - Fluorouracil) and FOLFIRI (Irinotecan - Leucovorin - Fluorouracil) as Second Line Treatment of Metastatic Colorectal Cancer

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Conditions Colorectal Cancer
Interventions FOLFIRI regimen FOLFOX regimen fluorouracil irinotecan hydrochloride leucovorin calcium oxaliplatin
Updated 7 times since 2017 Last updated: Jan 10, 2009 Started: Apr 30, 1999

A PHASE2 clinical study on Colorectal Cancer, this trial is ongoing. The trial is conducted by GERCOR - Multidisciplinary Oncology Cooperative Group and has accumulated 7 data snapshots since 1999. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

▶ Show 2 earlier versions

  1. Feb 2018 — Jun 2018 [monthly]

    Unknown Status PHASE2

  2. Jan 2017 — Feb 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Apr 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GERCOR - Multidisciplinary Oncology Cooperative Group
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Dijon, France, Le Mans, France, Lille, France, Lyon, France, Meulan-en-Yvelines, France, Montfermeil, France, Mulhouse, France, Neuilly-sur-Seine, France, Paris, France, Quincy-sous-Sénart, France and 3 more location s